CARsgen Therapeutics Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Zonghai Li

Chief executive officer

CN¥2.1m

Total compensation

CEO salary percentage	50.2%
CEO tenure	3.8yrs
CEO ownership	n/a
Management average tenure	3.2yrs
Board average tenure	4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Zonghai Li's remuneration changed compared to CARsgen Therapeutics Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-CN¥695m
Mar 31 2024	n/a	n/a	-CN¥721m
Dec 31 2023	CN¥2m	CN¥1m	-CN¥748m
Sep 30 2023	n/a	n/a	-CN¥834m
Jun 30 2023	n/a	n/a	-CN¥920m
Mar 31 2023	n/a	n/a	-CN¥906m
Dec 31 2022	CN¥2m	CN¥1m	-CN¥892m

Compensation vs Market: Zonghai's total compensation ($USD287.63K) is about average for companies of similar size in the Hong Kong market ($USD392.59K).

Compensation vs Earnings: Zonghai's compensation has increased whilst the company is unprofitable.

CEO

Zonghai Li (50 yo)

3.8yrs

Tenure

CN¥2,084,000

Compensation

Dr. Zonghai Li M.D., Ph D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 & Chairman of the Board. He ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Zonghai Li	Co-Founder	3.8yrs	CN¥2.08m	no data
Huamao Wang	Co-Founder	3.8yrs	CN¥2.11m	no data
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	no data
Hong Ma	Senior Vice President of Clinical Development	no data	no data	no data
Leigh Hsu	Senior Vice President of Business Development	no data	no data	no data
Raffaele Baffa	Chief Medical Officer	2.6yrs	no data	no data
Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	2.1yrs	no data	no data
Wing Yat Lui	Company Secretary	3.8yrs	no data	no data

3.2yrs

Average Tenure

51yo

Average Age

Experienced Management: 2171's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zonghai Li	Co-Founder	6.8yrs	CN¥2.08m	no data
Huamao Wang	Co-Founder	6.2yrs	CN¥2.11m	no data
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	no data
Ronggang Xie	Non-Executive Director	4.2yrs	no data	no data
Xiangke Zhao	Independent Non-Executive Director	1.3yrs	CN¥80.00k	no data
Bingsen Guo	Non-Executive Director	6.2yrs	no data	1.62% HK$ 62.4m
Guangmei Yan	Independent Non-Executive Director	3.4yrs	CN¥222.00k	no data
Huaqing Guo	Non-Executive Director	4.2yrs	no data	0.38% HK$ 14.6m
Wen Zhou	Independent Non-Executive Director	less than a year	no data	no data

4.2yrs

Average Tenure

47yo

Average Age

Experienced Board: 2171's board of directors are considered experienced (4.2 years average tenure).

CARsgen Therapeutics Holdings Management

Management criteria checks 3/4

Key information

Recent management updates

Non-Executive Director recently bought HK$903k worth of stock

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Recent updates

New major risk - Share price stability

CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel

Carsgen Therapeutics Holdings Limited Submits Application to Request Lifting Clinical Holds to FDA

CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China

CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Share price stability

Non-Executive Director recently bought HK$903k worth of stock

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New major risk - Share price stability

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Insider recently sold HK$14m worth of stock

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina

CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022

CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Insider recently sold HK$8.8m worth of stock

Insider recently sold HK$14m worth of stock

Insider recently sold HK$1.9m worth of stock

Insider recently sold HK$10m worth of stock

Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director

Insider recently sold HK$3.0m worth of stock

CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022

Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Therapeutics Holdings Limited Announces Approval from Center for Drug Evaluation of National Medical Products Administration of China for the Initiation of the CT041 Confirmatory Phase II Clinical Trial

CARsgen Therapeutics Holdings Limited Announces United States Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to CT041

CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Authorised by Health Canada

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age